{"filing":{"accession_number":"0001601485-26-000046","cik":"0001601485","ticker":"ELTX","company_name":"Elicio Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"angn-20260615.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000046/angn-20260615.htm"},"events":[{"id":10960,"run_id":9605,"accession_number":"0001601485-26-000046","anchor_item_number":"8.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The Company issued a press release on June 15, 2026 announcing Phase 2 clinical trial results for ELI-002 7P in pancreatic cancer and outlining a refined Phase 3 development strategy. While this is clinical trial data rather than financial earnings, it is a material disclosure of significant clinical progress that would affect investor assessment of the Company's pipeline and development trajectory. The attachment of a press release and conference call presentation indicates this is a formal material announcement comparable in disclosure significance to an earnings release.","company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7419,"accession_number":"0001601485-26-000046","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Company issued a press release on June 15, 2026 announcing Phase 2 clinical trial results for ELI-002 7P in pancreatic cancer and outlining a refined Phase 3 development strategy. While this is clinical trial data rather than financial earnings, it is a material disclosure of significant clinical progress that would affect investor assessment of the Company's pipeline and development trajectory. The attachment of a press release and conference call presentation indicates this is a formal material announcement comparable in disclosure significance to an earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:22:06.887851+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7419,"accession_number":"0001601485-26-000046","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Company issued a press release on June 15, 2026 announcing Phase 2 clinical trial results for ELI-002 7P in pancreatic cancer and outlining a refined Phase 3 development strategy. While this is clinical trial data rather than financial earnings, it is a material disclosure of significant clinical progress that would affect investor assessment of the Company's pipeline and development trajectory. The attachment of a press release and conference call presentation indicates this is a formal material announcement comparable in disclosure significance to an earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:22:06.887851+00:00","company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","filing_date":"2026-06-15"}]}